潘南金在急性心肌梗死治疗中的作用

目的探讨潘南金在急性心肌梗死(AMI)治疗中改善恶性心律失常及心功能的作用。方法将患者随机分为潘南金组及对照组各40例,在AMI常规治疗基础上,潘南金组予潘南金注射液40mL加入5%葡萄糖注射液500mL中静脉点滴,1次/d;同时加服片剂2片/次,3次/d。对照组则予极化液静点,1次/d。2组均在CCU监护1周后转入普通病房,共治疗3～4周。结果恶性心律失常发生率潘南金组为25%,对照组为65%,2组比较P<0.01。出院时心功能NYHA分级改善2级以上者,潘南金组为58%,对照组为45%,2组比较P<0.05。结论对AMI患者尽早应用潘南金治疗,可明显降低恶性心律失常发生率和改善心功能,且不良反应少,可列为常规用药。     

老年冠心病患者的动态心电图观察

对97例老年冠心病患者进行动态心电图观察,共检出97例患者缺血性ST段发作347阵,心率减慢时发生缺血48例(49.5％),全程无症状者75例(77.4%),缺血时有无胸痛与ST段下降程度无必然联系。     

葡萄糖酸镁灌胃对大鼠异丙肾上腺素心肌损伤的影响

用大鼠异丙肾上腺素心肌损伤模型,研究了葡萄糖酸镁胃内给药的心肌保护作用。结果表明,葡萄糖酸镁胃内给药能减少异丙肾上腺素所致的心肌细胞Mg~(2+)丢失和Ca~(2+)聚积,减轻心肌组织脂质过氧化损害,抑制细胞内乳酸脱氢酶的释放,并能显著地减轻异丙肾上腺素引起的心肌肥大或/和水肿等病理损伤。证实了葡萄糖酸镁胃肠道给药具有一定的心肌保护作用,为其临床应用提供了实验依据。     

Reperfused myocardial infarctions on T1- and susceptibility-enhanced MRI: Evidence for loss of compartmentalization of contrast media

The purpose of this study was to characterize the contrast caused by a susceptibility MRI contrast agents, on spin echo T₂-weighted imaging of reperfused myocardial infarction. Our interest in this model focused on the expected requirement that such agents be compartmentalized in the tissue to cause signal loss on spin echo images, a condition which may not be present in reperfused infarcted myocardium. Accordingly, nine rats were subjected to 2 h of left coronary artery occlusion followed by 3 ± 0.5 h of reperfusion prior to administration of contrast media. Three sets of MR images were acquired: (a) baseline axial images at the midventricle, both T₁-weighted (TR/TE = 300/20) and T₂-weighted (TR/TE = 1500/60); (b) T₁-weighted images after administering a T₁-enhancing agent, Gd-DTPA-BMA (0.2 mmol/kg), to document that contrast media is delivered to the reperfused infarction; and (c) T₂-weighted images after administering the susceptibility agent, Dy-DTPA-BMA (1.0 mmol/kg). Gadolinium-enhanced T₁ images depicted reperfused infarction as regions with greatly enhanced signal intensity compared with unin-farcted myocardium, indicating that contrast agent was delivered to the infarcted zone. Dysprosium-enhanced T₁ images depicted the injury as a region of persistent signal intensity relative to depletion of signal in normal myocardium, consistent with failure of the contrast agent to cause signal loss. Similar infarction sizes were observed for unenhanced T₂-weighted images (33 ± 5%), gadolinium-enhanced T₁ weighted images (36 ± 5%) and postmortem staining (30 ± 6%); strong correlations (r > 0.9) were noted in comparisons of these data. Dysprosium-enhanced images exhibited a smaller region of differential signal presumed to be infarction (20 ± 5%, P < 0.05) and weak correlations (r < 0.75) with the other measurements. We conclude that the smaller infarction depicted on dysprosium-enhanced images is a subregion of the true infarction in which myocardial necrosis is sufficiently advanced that the agent is homogeneously distributed throughout all tissue compartments, preventing T₂*-dependent phase loss on spin echo images.     

Beta-adrenergic blockade following thrombolytic therapy: Is it helpful or harmful?

Beta-adrenergic blockade has been a mainstay in the treatment of patients with acute myocardial infarction for nearly two decades. Clearly, it has withstood the test of time. The emergence of thrombolytic therapy, however, has shifted the medical community's focus, raising questions as to the benefit of beta-adrenergic blockade. Although further investigation is warranted, the available evidence suggests that beta blockers can be given safely to selected patients following coronary thrombolysis, particularly in the absence of moderate to severe left ventricular dysfunction.     

Quality of life on enalapril after acute myocardial infarction

Quality of life was assessed 4–6 months after an acutemyocardial infarction in a randomized double-blind study ofenalapril versus placebo. Quality of life was evaluated usingthe Nottingham Health Profile (NHP), the Physical Symptoms DistressIndex (PSDI), the Work Performance Scale (WPS) and the LifeSatisfaction Index (LSI). The study comprised 36 women (aged46–85 years, mean 68) and 96 males (aged 39–81 years,mean 62). Quality of life did not differ significantly between patientstreated with enalapril versus placebo. The scores were (enalaprilvs placebo, mean± SE): average NHP 15.4 ± 2.3vs 17.1 ± 2.3; PSDI 9.5± 1.0 vs 10.8 ±0.9; WPS 19.8 ± 2.0 vs 19.4 ± 1.4; LSI 24.1 ±1.0 vs 22.5 ±1.4. Men reported a better quality of lifethan women on most assessments, and non-smokers and ex-smokersbetter than smokers. Patients with moderate or severe anginapectoris had a worse quality of life measured by PSDI and NHPthan patients with minimal or no angina pectoris. Patients withcongestive heart failure had a higher PSDI than those without(13.6 ± 1.7 vs 9.4 ± 0.7, P<0.05), while nosignificant differences were observed in the NHP scores. In conclusion, quality of life was similar in enalapril andplacebo- treated patients after an acute myocardial infarction.However, it was reduced in patients with angina pectoris orheart failure and in those who continued smoking.     

三七皂甙对心肌腺苷三磷酸酶的影响(英文)

三七总皂甙(PNS)能抑制心肌总ATP酶活力,但对Na~( )-K~( )-ATP酶无明显影响。三七皂甙单体Rb_1及Rg_1对心肌总ATP酶活力均有抑制作用,但Rb_1的抑制效力显著大于Rg_1·Rb_1能抑制豚鼠离体心房肌的自律性和收缩性,Rg_1也能抑制豚鼠离体心房肌的自律性,但对心房肌的收缩性却无明显影响。提示PNS抑制心肌收缩力这一作用的主要有效成份是Rb_1·     

床旁临时起搏器作为AMI的常备急救设备及其在基层医院推广应用研究

目的 床旁临时起搏器作为急性心肌梗死（AMI）的常备急救设备的价值及其在基层医院推广应用的可行性研究。方法 回顾性研究分析2001-2003年间不能床旁植入临时起搏器与2004-2005年能床旁植入临床起搏器抢救AMI的住院病死率、心衰、心源性休克、2mo后再次住院发生率。临时起搏器植入术安全性的指标比较。结果 不能床旁植入临时起搏器组的住院病死率为14．58％，心衰发生率为27．08％，心源性休克发生率为12．5％，2mo后再次住院发生率为16．67％。床旁植入临时起搏器组的住院病死率为3．57％，心衰发生率为7．14％，心源性休克发生率为3．57％，2mo后再次住院发生率为3．57％，两组相比p〈0．01有显著性差异。而起搏器植入的安全性指标：起搏器植入成功率为100％，脱位率为10．7％，并发症发生率为14.3％，住院病死率3．57％。结论 床旁临时起搏器抢救AMI住院病死率低，心衰发生率、心源性休克发生率及2mo后再次住院发生率低，应作为AMI抢救的常备急救设备，另外床旁临时起搏器植入是安全的、有效的，成功率高，操作不难，在基层医院（二甲医院）可推广应用。     

~(123)I-MIBG心肌显像预测依那普利对扩张型心肌病患者治疗效果的临床价值

目的探讨123I-MIBG心肌显像在治疗前预测依那普利对扩张型心肌病(DCM)患者治疗效果的临床价值。方法对24例DCM患者于依那普利治疗前行早期(20min)及延迟(3h)123I-MIBG心肌显像,采用心/上纵隔(H/M)比和心脏放射性洗脱率(WR)作为相对半定量计数分析,与超声心功能参数进行对比。根据123I-MI-BG心肌显像延迟相的H/M分为3组延迟H/M≥1.7为组Ⅰ,1.5<延迟H/M<1.7为组Ⅱ,延迟H/M≤1.5为组Ⅲ。组Ⅰ和组Ⅱ在平均治疗4.5个月后重复以上检查。结果治疗前3组间超声心功能参数比较均无统计学差异。治疗后组Ⅰ的左室射血分数(LVEF)和左室收缩末径(LVDs)明显改善,早期H/M和延迟H/M均明显改善(P<0.05),而WR无明显变化。治疗后组Ⅱ的延迟H/M明显改善(P<0.05),而早期H/M和WR均无明显变化,心功能参数也无改善。组Ⅰ和组Ⅱ患者均能耐受依那普利治疗,而组Ⅲ患者均不能耐受依那普利治疗。结论123I-MIBG心肌显像在治疗前预测依那普利对DCM患者的治疗效果方面有一定价值。     

内皮素在评价不阻断升主动脉低温室颤对心肌保护作用中的应用

①目的探讨体外循环条件下低温室颤技术对心肌的保护作用。②方法14只健康成年犬随机分为两组，低温停跳组(n=7)与低温室颤组(n=7)，分别检测两组手术前、手术1、2小时和复跳后1小时4个时间点血内皮素(ET)的水平。③结果室颤组ET水平明显低于停跳组。④结论通过内皮素水平的变化，说明体外循环条件下低温室颤技术是一种安全、有效的心肌保护方式，优于传统低温停跳技术。